1.
Coronary angioplasty vs. coronary artery bypass surgery: the Randomized
2.
3.
4.
Intervention Treatment of Angina (RITA) trial. Lancet 341: 573–580,
1993
Lüscher TF, Vanhoutte PM: The Endothelium: Modulator of cardiovascular function. CRC Press, Boca Raton, pp 1–215, 1990
Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (London)
288: 373–376, 1980
Guarini S, Bazzani C, Bertolini A: Resuscitating effect of melanocortin peptides after prolonged respiratory arrest. Br J Pharmacol 121: 1454–
1460, 1997

8.
9.
5.
6.
7.
Bredt DS, Hwang PM, Snyder SH: Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature (London) 347: 768–770,
1990
Lüscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, von
Segesser L, Yang ZH, Turina M, Gradel E, Weber E, et al: Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 319: 462–467, 1988
Moncada S, Vane VR: Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin.
Pharmacol Rev 30: 293–331, 1979
Vanhoutte PM: Vascular Physiology: the end of the quest? Nature
(London) 260: H13-H20, 1987
De Mey JG, Vanhoutte PM: Heterogenous behavior of the canine arterial and venous wall. Importance of the endothelium. Circ Res 51: 439–447,
1982

10.
11.
12.
13.
Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T: A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl 6: S188–
91, 1988
Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, Yanagisawa M:
ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78: 473–485, 1994
Boulanger C, Lüscher TF: Release of endothelin from the porcine aorta.
Inhibition by endothelium-derived nitric oxide. J Clin Invest 85: 587–590,
1990
Kiowski W, Lüscher TF, Linder L, Buhler FR: Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation
83: 469–475, 1991

14.
15.
16.
17.
Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S: Cloning and expression of a cDNA encoding an endothelin receptor [see comments].
Nature (London) 348: 730–732, 1990
Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K,
Masaki T: Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature (London) 348: 732–735, 1990
Wenzel RR, Lüscher TF: Endothelin receptor antagonists as new tools to inhibit endothelin induced vasoconstriction in humans: comparison with calcium channel blockers. In: The endothelium in cardiovascular disease.
Springer, Berlin Heidelberg New York, 1995, pp 129–147
Wenzel RR, Noll G, Lüscher TF: Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension 23: 581–586,
1994

18.
19.
20.
21.
22.
Wenzel RR, Duthiers N, Noll G, Bucher J, Kaufmann U, Lüscher TF:
Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease. Circulation 94: 316–322, 1996
Ng KK, Vane JR: Conversion of angiotensin I to angiotensin II. Nature
(London) 216: 762–766, 1967
Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW:
Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141–1148, 1994
Linder L, Kiowski W, Buhler FR, Lüscher TF: Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation
81: 1762–1767, 1990
Panza JA, Quyyumi AA, Brush JJ, Epstein SE: Abnormal endotheliumdependent vascular relaxation in patients with essential hypertension. N
Engl J Med 323: 22–27, 1990

23.
24.
25.
26.
27.
Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM: Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med 330: 1036–1040, 1994
Vaziri ND, Ni Z, Oveisi F: Upregulation of renal and vascular Nitric oxide synthase in young spontaneously hypertensive rats. Hypertension 31:
1248–1254, 1999
Cosentino F, Patton S, d'Uscio LV, Werner ER, Werner-Felmayer G,
Moreau, P, Malinski T, Lüscher TF: Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 101: 1530–
1537, 1998
Lüscher TF, Vanhoutte PM, Raij L: Antihypertensive treatment normalizes decreased endothelium- dependent relaxations in rats with saltinduced hypertension. Hypertension 9: III193–7, 1987
Ni Z, Oveisi F, Vaziri ND: Nitric oxide synthase isotype expression in salt-sensitive and salt-resistant Dahl rats. Hypertension 34: 552–557, 1999

28.
29.
30.
31.
Lariviere R, Deng LY, Day R, Sventek P, Thibault G, Schiffrin EL:
Increased endothelin-1 gene expression in the endothelium of coronary arteries and endocardium in the DOCA-salt hypertensive rat. J Mol Cell
Cardiol 27: 2123–2131, 1995
Barton M, Vos I, Shaw S, Boer P, d'Uscio LV, Gröne HJ, Rabelink TJ,
Lattmann T, Moreau P, Lüscher TF: Dysfunctional renal nitric oxide synthase as a determinant of salt- sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophyandGlomerulosclerosis. J Am Soc Nephrol 11: 835–845, 2000
Taddei S, Virdis A, Mattei P, Salvetti A: Vasodilatation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 21:
929–933, 1993
Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N: Basal nitric oxide synthesis in essential hypertension. Lancet 349: 837–842,
1997

32.
33.
34.
35.
Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ,
Schneider B, Waldhausl W, Binder BR: Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267: 16066–16068, 1992
Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl
J Med 338: 784–790, 1998
Harrison DG, Freiman PC, Armstrong ML, Marcus ML, Heistadt DD:
Alterations of vascular reactivity in atherosclerosis. Circ Res 61: 1174–
1180, 1987
Tanner FC, Noll G, Boulanger CM, Luscher, TF.: Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium- derived nitric oxide. Circulation 83:
2012–2020, 1991

36.
37.
38.
39.
Sparrow CP, Doebber TW, Olszewski J, Wu MS, Ventre J, Stevens KA,
Chao YS: Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine. J Clin Invest 89: 1885–
1891, 1992
Zeiher AM, Drexler H, Saurbier B, Just H: Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 92:
652–662, 1993
Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett
JC, JR.: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325: 997–1001, 1991
Winkles JA, Alberts GF, Brogi E, Libby P: Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries.
Biochem Biophys Res Commun 191: 1081–1088, 1993

40.
41.
Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, Lüscher TF:
Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 70: 1191–
1197, 1992
Lüscher TF, Noll G: The endothelium in coronary vascular control. In:
Braunwald E (ed) Heart disease, vol 1. Philadelphia, pp 1–10, 1996

1.
Angouras D, Sokolis DP, Dosios T, Kostomitsopoulos N, Boudoulas H,
Skalkeas G, Karayannacos PE. Effect of impaired vasa vasorum flow on
2.
3.
4.
the structure and mechanics of the thoracic aorta: implications for the pathogenesis of aortic dissection. Eur J Cardiothorac Surg 2000; 17/4:
468–473
Bataineh A, Raij L. Angiotensin II, nitric oxide, and end-organ damage in hypertension. Kidney Int Suppl 1998; 68: S14–S19
Bayes-Genis A, Guindo J, Vinolas X, Tomas L, Elosua R, Duran I, Bayes dL. Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension and their influences on prognosis. Am J Cardiol 1995; 76/13:
54D–59D
Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll
Cardiol 1993; 22/4: 1111–1116

5.
6.
7.
8.
9.
Böhm M, Castellano M, Paul M, Erdmann E. Cardiac norepinephrine, beta-adrenoceptors, and Gi alpha-proteins in prehypertensive and hypertensive spontaneously hypertensive rats. J Cardiovasc Pharmacol
1994; 23/6: 980–987
Böhm M, Flesch M, Schnabel P. Role of G-proteins in altered betaadrenergic responsiveness in the failing and hypertrophied myocardium.
Basic Res Cardiol 1996; 91 Suppl 2: 47–51
Böhm M, Flesch M, Schnabel P. Beta-adrenergic signal transduction in the failing and hypertrophied myocardium. J Mol Med 1997; 75/11–12: 842–
848
Bourcier T, Sukhova G, Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997; 272/25: 15817–
15824
Böhm M, Zolk O, Flesch M, Schiffer F, Schnabel P, Stasch JP, Knorr A.

10.
11.
12.
13.
Effects of angiotensin II type 1 receptor blockade and angiotensinconverting enzyme inhibition on cardiac beta-adrenergic signal transduction. Hypertension 1998; 31/3: 747–754
Brilla CG, Reams GP, Maisch B, Weber KT. Renin-angiotensin system and myocardial fibrosis in hypertension: regulation of the myocardial collagen matrix. Eur Heart J 1993; 14 Suppl J: 57–61
Charpentier F, Baudet S, Le Marec H. Triggered activity as a possible mechanism for arrhythmias in ventricular hypertrophy. Pacing Clin
Electrophysiol 1991; 14/11 Pt 2: 1735–1741
Chien KR, Knowlton KU, Zhu H, Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J 1991; 5/15: 3037–3046
Clarkson PB, Wheeldon NM, MacLeod C, Tennent M, MacDonald TM.
Effects of angiotensin II and aldosterone on diastolic function in vivo in normal man. Clin Sci 1994; 87/4: 397–401

14.
15.
16.
17.
18.
Colucci WS. Molecular and cellular mechanisms of myocardial failure.
Am J Cardiol 1997; 80/11A: 15L–25L
Daily PO, Trueblood HW, Stinson EB, Wuerflein RD, Shumway NE.
Management of acute aortic dissections. Ann Thorac Surg 1970; 10/3:
237–247
De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB,
Gimbrone MA, Jr., Shin WS, Liao JK. Nitric oxide decreases cytokineinduced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin
Invest 1995; 96/1: 60–68 de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman
MH, Laragh JH. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J
Am Coll Cardiol 1994; 23/6: 1444–1451 de Simone G, Palmieri V. Diastolic dysfunction in arterial hypertension. J

19.
20.
21.
22.
23.
Clin Hypertens 2001; 3/1: 22–27
DeBakey ME, McCollum CH, Crawford ES, Morris GC, Jr., Howell J,
Noon GP, Lawrie G. Dissection and dissecting aneurysms of the aorta: twenty-year follow-up of five hundred twenty-seven patients treated surgically. Surgery 1982; 92/6: 1118–1134
Devereux RB, de Simone G, Ganau A, Koren MJ, Mensah GA, Roman
MJ. Left ventricular hypertrophy and hypertension. Clin Exp Hypertens
1993; 15/6: 1025–1032
Dostal DE, Hunt RA, Kule CE, Bhat GJ, Karoor V, McWhinney CD,
Baker KM. Molecular mechanisms of angiotensin II in modulating cardiac function: intracardiac effects and signal transduction pathways. J Mol Cell
Cardiol 1997; 29/11: 2893–2902
Flachskampf FA, Daniel WG. Aortic dissection. Cardiol Clin 2000; 18/4:
807–817
Flesch M, Erdmann E, Böhm M. Changes in beta-adrenoceptors and G-

24.
25.
26.
proteins during the transition from cardiac hypertrophy to heart failure. J
Card Fail 1996; 2/4 Suppl: S35–S43
Flesch M, Schwinger RH, Schiffer F, Frank K, Sudkamp M, Kuhn-
Regnier F, Arnold G, Böhm M. Evidence for functional relevance of an enhanced expression of the Na+/-Ca2+ exchanger in failing human myocardium. Circulation 1996; 94/5: 992–1002
Flesch M, Schwinger RH, Schnabel P, Schiffer F, van G, I, Bavendiek U,
Sudkamp M, Kuhn-Regnier F, Böhm M. Sarcoplasmic reticulum
Ca2+ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy. J Mol Med 1996;
74/6: 321–332
Ford CM, Li S, Pickering JG. Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT1 receptor, transforming growth factor-beta, and tyrosine phosphorylation.
Arterioscler Thromb Vasc Biol 1999; 19/8: 1843–1851

27.
28.
29.
30.
31.
32.
Fortuno MA, Ravassa S, Fortuno A, Zalba G, Diez J. Cardiomyocyte apoptotic cell death in arterial hypertension: mechanisms and potential management. Hypertension 2001; 38/6: 1406–1412
Frohlich ED. Fibrosis and ischemia: the real risks in hypertensive heart disease. Am J Hypertens 2001; 14/6 Pt 2: 194S–199S
Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.
Circ Res 1988; 62/4: 749–756
Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol 2002; 22/9: 1370–1380
Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta.
Arterioscler Thromb Vasc Biol 1996; 16/1: 19–27
Hagan PG, Nienaber CA, Isselbacher EM, Bruckman D, Karavite DJ,

35.
36.
37.
33.
34.
Russman PL, Evangelista A, Fattori R, Suzuki T, Oh JK, Moore AG,
Malouf JF, Pape LA, Gaca C, Sechtem U, Lenferink S, Deutsch HJ,
Diedrichs H, Robles J, Llovet A, Gilon D, Das SK, Armstrong WF, Deeb
GM, Eagle KA. The International Registry of Acute Aortic Dissection
/IRAD: new insights into an old disease. JAMA 2000; 283/7: 897–903
Hare JM. Oxidative stress and apoptosis in heart failure progression. Circ
Res 2001; 89/3: 198–200
Houser SR, Piacentino V, III, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 2000; 32/9:
1595–1607
Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000; 85/2: 251–255
Katz AM. Proliferative signaling and disease progression in heart failure.
Circ J 2002; 66/3: 225–231
Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery

38.
39.
40.
41.
42.
disease. Curr Opin Lipidol 2001; 12/4: 383–389
Kitamura M, Hashimoto A, Akimoto T, Tagusari O, Aomi S, Koyanagi H.
Operation for type A aortic dissection: introduction of retrograde cerebral perfusion. Ann Thorac Surg 1995; 59/5: 1195–1199
Kubisch C, Wollnik B, Maass A, Meyer R, Vetter H, Neyses L.
Immediate-early gene induction by repetitive mechanical but not electrical activity in adult rat cardiomyocytes. FEBS Lett 1993; 335/1: 37–40
Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP.
Risk of ventricular arrhythmias in left ventricular hypertrophy: the
Framingham Heart Study. Am J Cardiol 1987; 60/7: 560–565
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322/22: 1561–1566
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis.
Circulation 2002; 105/9: 1135–1143

43.
44.
45.
46.
47.
48.
Libby P, Sukhova G, Lee RT, Liao JK. Molecular biology of atherosclerosis. Int J Cardiol 1997; 62 Suppl 2: S23–S29
Lijnen P, Petrov V. Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. J Mol Cell Cardiol 1999; 31/5: 949–970
Lin M, Sumimoto T, Hiwada K. Left ventricular geometry and cardiac function in mild to moderate essential hypertension. Hypertens Res 1995;
18/2: 151–157
Lopez JJ, Lorell BH, Ingelfinger JR, Weinberg EO, Schunkert H, Diamant
D, Tang SS. Distribution and function of cardiac angiotensin AT1- and
AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol 1994;
267/2 Pt 2: H844–H852
Marcus ML, Heistad DD, Armstrong ML, Abboud FM. Effects of chronic hypertension on vasa vasorum in the thoracic aorta. Cardiovasc Res 1985;
19/12: 777–781
McLenachan JM, Dargie HJ. Ventricular arrhythmias in hypertensive left

49.
50.
51.
52.
ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 1990;
3/10: 735–740
Meszaros J, Khananshvili D, Hart G. Mechanisms underlying delayed afterdepolarizations in hypertrophied left ventricular myocytes of rats. Am
J Physiol Heart Circ Physiol 2001; 281/2: H903–H914
Narula J, Arbustini E, Chandrashekhar Y, Schwaiger M. Apoptosis and the systolic dysfunction in congestive heart failure. Story of apoptosis interruptus and zombie myocytes. Cardiol Clin 2001; 19/1: 113–126
Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ,
Schmidt U, Semigran MJ, Dec GW, Khaw BA. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996; 335/16: 1182–1189
Nickenig G, Geisen G, Vetter H, Sachinidis A. Characterization of angiotensin receptors on human skin fibroblasts. J Mol Med 1997; 75/3:
217–222

53.
54.
55.
56.
57.
Nickenig G, Laufs U, Schnabel P, Knorr A, Paul M, Böhm MP. Downregulation of aortic and cardiac AT1 receptor gene expression in transgenic /mRen-2) 27 rats. Br J Pharmacol 1997; 121/1: 134–140
O'Rourke M. Mechanical principles in arterial disease. Hypertension 1995;
26/1: 2–9
Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey
KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor
A. Proc Natl Acad Sci U S A 1997; 94/26: 14730–14735
Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995;
270/23: 14214–14219
Ren JF, Pancholy SB, Iskandrian AS, Lighty GW, Jr., Mallavarapu C,
Segal BL. Doppler echocardiographic evaluation of the spectrum of left ventricular diastolic dysfunction in essential hypertension. Am Heart J

58.
59.
60.
61.
1994; 127/4 Pt 1: 906–913
Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998; 101/4: 731–736
Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997; 59: 551–71.: 551–
571
Schunkert H, Jackson B, Tang SS, Schoen FJ, Smits JF, Apstein CS,
Lorell BH. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 1993; 87/4:
1328–1339
Schwartzkopff B, Mundhenke M, Strauer BE. Remodelling of intramyocardial arterioles and extracellular matrix in patients with arterial hypertension and impaired coronary reserve. Eur Heart J 1995; 16 Suppl I:
82–86

62.
63.
64.
65.
66.
Shin WS, Hong YH, Peng HB, De Caterina R, Libby P, Liao JK. Nitric oxide attenuates vascular smooth muscle cell activation by interferongamma. The role of constitutive NF-kappa B activity. J Biol Chem 1996;
271/19: 11317–11324
Sipido KR, Volders PG, de Groot SH, Verdonck F, Van de WF, Wellens
HJ, Vos MA. Enhanced Ca/2+) release and Na/Ca exchange activity in hypertrophied canine ventricular myocytes: potential link between contractile adaptation and arrhythmogenesis. Circulation 2000; 102/17:
2137–2144
Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol
Heart Circ Physiol 2002
Sun Y. The renin-angiotensin-aldosterone system and vascular remodeling. Congest Heart Fail 2002; 8/1: 11–16
Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin II/type 1A)

67.
68.
69.
70.
71.
receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res 1993; 73/3: 439–447
Swynghedauw B, Chevalier B, Charlemagne D, Mansier P, Carre F.
Cardiac hypertrophy, arrhythmogenicity and the new myocardial phenotype. II. The cellular adaptational process. Cardiovasc Res 1997;
35/1: 6–12
Tin LL, Beevers DG, Lip GY. Hypertension, left ventricular hypertrophy, and sudden death. Curr Cardiol Rep 2002; 4/6: 449–457
Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB,
Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345/18: 1291–1297
Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart
Study. Circulation 1994; 89/2: 724–730
Verdecchia P, Porcellati C, Zampi I, Schillaci G, Gatteschi C, Battistelli

72.
73.
74.
75.
M, Bartoccini C, Borgioni C, Ciucci A. Asymmetric left ventricular remodeling due to isolated septal thickening in patients with systemic hypertension and normal left ventricular masses. Am J Cardiol 1994; 73/4:
247–252
Vogt M, Strauer BE. Systolic ventricular dysfunction and heart failure due to coronary microangiopathy in hypertensive heart disease. Am J Cardiol
1995; 76/13: 48D–53D
Wang ZQ, Moore AF, Ozono R, Siragy HM, Carey RM.
Immunolocalization of subtype 2 angiotensin II receptor protein in rat heart. Hypertension 1998; 32/1: 78–83
Wolk R. Arrhythmogenic mechanisms in left ventricular hypertrophy.
Europace 2000; 2/3: 216–223
Yamakawa T, Tanaka S, Numaguchi K, Yamakawa Y, Motley ED,
Ichihara S, Inagami T. Involvement of Rho-kinase in angiotensin IIinduced hypertrophy of rat vascular smooth muscle cells. Hypertension

76.
77.
2000; 35/1 Pt 2: 313–318
Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84/5:
1984–1992
Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83/2:
391–401

1.
Anonymous (1992) Clinical trial of nimodipine in acute ischemic stroke.
The American Nimodipine Study Group. Stroke 23: 3–8
2.
3.
4.
5.
Anonymous (1995) Cholesterol, diastolic blood pressure, and stroke:
13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 346: 1647–1653
Anonymous (1995) NINDS rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333: 1581–
1587
Anonymous (1998) Blood pressure, cholesterol, and stroke in eastern Asia.
Eastern Stroke and Coronary Heart Disease Collaborative Research
Group. Lancet 352: 1801–1807
Anonymous (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK
Prospective Diabetes Study Group. BMJ 317: 703–713

6.
7.
8.
9.
Anonymous (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). ALLHAT
Collaborative Research Group. JAMA 283: 1967–1975
Anonymous (2001) Randomised trial of a perindopril-based bloodpressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041
Anonymous (2002) Die Gesundheitsberichterstattung des Bundes
Statistisches Bundesamt – Gesundheitsbericht für Deutschland 1998,
Wiesbaden
Adler AI, Stratton IM, Neil HA et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321: 412–
419

11.
12.
13.
14.
10.
15.
Ahmed N, Nasman P, Wahlgren NG (2000) Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke 31:
1250–1255
Andersson OK, Almgren T, Persson B et al. (1998) Survival in treated hypertension: follow up study after two decades. BMJ 317: 167–171
Astrup J, Siesjo BK, Symon L (1981) Thresholds in cerebral ischemia – the ischemic penumbra. Stroke 12: 723–725
Blumenfeld JD, Laragh JH (2001) Management of hypertensive crises: the scientific basis for treatment decisions. Am J Hypertens 14: 1154–1167
Broderick JP, Brott T, Tomsick T, Miller R, Huster G (1993) Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. J
Neurosurg 78: 188–191
Broderick JP, Adams HP Jr, Barsan W et al. (1999) Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for

16.
17.
18.
19.
healthcare professionals from a special writing group of the Stroke
Council, American Heart Association. Stroke 30: 905–915
Brott T, Broderick J, Kothari R et al. (1997) Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 28: 1–5
Brott T, Bogousslavsky J (2000) Treatment of acute ischemic stroke. N
Engl J Med 343: 710–722
Cushing H. (1903) The blood-pressure reaction of acute cerebral compression, illustrated by cases of intracranial hemorrhage. Am J Med
Sci 125: 1017–1045
Collins R, Peto R, MacMahon S et al. (1990) Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.
Lancet 335: 827–838

20.
21.
22.
23.
24.
Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH (1995)
Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 155: 701–709
Dahlöf B, Devereux RB, Kjeldsen SE et al., The LIFE Study Group (2002)
Cardiovascular morbidity and mortality in the Losartan Intervention For
Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359: 995–1003
Dandapani BK, Suzuki S, Kelley RE, Reyes-Iglesias Y, Duncan RC
(1995) Relation between blood pressure and outcome in intracerebral hemorrhage. Stroke 26: 21–24
Diringer MN (1993) Intracerebral hemorrhage: pathophysiology and management. Crit Care Med 21: 1591–1603
Dirnagl U, Pulsinelli W (1990) Autoregulation of cerebral blood flow in experimental focal brain ischemia. J Cereb Blood Flow Metab 10: 327–
336

25.
26.
27.
28.
29.
30.
Dickinson CJ (2001) Why are strokes related to hypertension? Classic studies and hypotheses revisited. J Hypertens 19: 1515–1521
Einhäupl KM, Masuhr F (1999) Hypertension and Stroke. Diabetes und
Stoffwechsel 8, Suppl.2: 14–18
Fang XH, Longstreth WT Jr, Li SC et al. (2001) Longitudinal study of blood pressure and stroke in over 37,000 People in China. Cerebrovasc
Dis 11: 225–229
Fogelholm R, Avikainen S, Murros K (1997) Prognostic value and determinants of first-day mean arterial pressure in spontaneous supratentorial intracerebral hemorrhage. Stroke 28: 1396–1400
Garcia JH, Ho KL (1992) Pathology of hypertensive arteriopathy.
Neurosurg Clin N Am 3: 497–507
Gueyffier F, Boissel JP, Boutitie F et al. (1997) Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the

31.
32.
33.
evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 28: 2557–2562
Gueyffier F, Bulpitt C, Boissel JP et al. (1999) Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials.
INDANA Group. Lancet 353: 793–796
Hacke W, Kaste M, Skyhoj Olsen T, Orgogozo JM, Bogousslavsky J
(2000) European Stroke Initiative (EUSI) recommendations for stroke management. The European Stroke Initiative Writing Committee. Eur J
Neurol 7: 607–623
Hansson L, Zanchetti A, Carruthers SG et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment
(HOT) randomised trial. HOT Study Group. Lancet 351: 1755–1762

34.
35.
36.
37.
38.
Hennes HJ, Jantzen JP (1994) Effects of fenoldopam on intracranial pressure and hemodynamic variables at normal and elevated intracranial pressure in anesthetized pigs. J Neurosurg Anesthesiol 6: 175–181
Hoes AW, Grobbee DE, Lubsen J (1995) Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension. J
Hypertens 13: 805–811
Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS (1994) Effect of blood pressure and diabetes on stroke in progression. Lancet 344: 156–159
Jørgensen HS, Nakayama H, Raaschou HO et al. (1995) Stroke rehabilitation: Outcome and Speed of recovery in stroke. Part I: Outcome.
The Copenhagen Stroke Study. Arch Phys Med Rehabil 76: 399–405
Kolominsky-Rabas PL, Sarti C, Heuschmann PU et al. (1998) A prospective community-based study of stroke in Germany-the Erlangen
Stroke Project (ESPro): incidence and case fatality at 1, 3, and 12 months.
Stroke 29: 2501–2506

39.
40.
41.
42.
43.
Lindenstrom E, Boysen G, Nyboe J (1995) Influence of systolic and diastolic blood pressure on stroke risk: a prospective observational study.
Am J Epidemiol 142: 1279–1290
Lisk DR, Grotta JC, Lamki LM et al. (1993) Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Arch Neurol 50: 855–862
MacMahon S, Peto R, Cutler J et al. (1990) Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.
Lancet 335: 765–774
MacMahon S, Rodgers A (1994) Blood pressure, antihypertensive treatment and stroke risk. J Hypertens Suppl 12: S5–S14
Masuhr F, Einhaupl K (1999) Treatment of ischaemic stroke. Thromb
Haemost 82 Suppl 1: 85–91

44.
45.
46.
47.
48.
Messerli FH, Grossman E, Goldbourt U (2001) Antihypertensive therapy in diabetic hypertensive patients. Am J Hypertens 14: 12S-16S
Morfis L, Schwartz RS, Poulos R, Howes LG (1997) Blood pressure changes in acute cerebral infarction and hemorrhage. Stroke 28: 1401–
1405
Nielsen WB, Lindenstrom E, Vestbo J, Jensen GB (1997) Is diastolic hypertension an independent risk factor for stroke in the presence of normal systolic blood pressure in the middle-aged and elderly? Am J
Hypertens 10: 634–639
O'Donnell CJ, Ridker PM, Glynn RJ et al. (1997) Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation 95: 1132–1137
Olsen KS, Svendsen LB, Larsen FS, Paulson OB (1995) Effect of labetalol on cerebral blood flow, oxygen metabolism and autoregulation in healthy humans. Br J Anaesth 75: 51–54

49.
50.
51.
52.
Powers WJ, Zazulia AR, Videen TO et al. (2001) Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage. Neurology 57: 18–24
Puchstein C, van Aken H, Hidding J, Anger C, Lawin P (1983) Treatment of hypertension with labetalol in neurosurgical practice. Influence of labetalol on cerebral perfusion pressure in dogs without and with intracranial mass lesions. Acta Neurochir (Wien) 67: 283–290
Qureshi AI, Bliwise DL, Bliwise NG, Akbar MS, Uzen G, Frankel MR
(1999) Rate of 24-hour blood pressure decline and mortality after spontaneous intracerebral hemorrhage: a retrospective analysis with a random effects regression model. Crit Care Med 27: 480–485
Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF
(2001) Spontaneous intracerebral hemorrhage. N Engl J Med 344: 1450–
1460

53.
54.
55.
56.
57.
Saloheimo P, Juvela S, Hillbom M (2001) Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. Stroke 32: 399–404
Schrader J, Rothemeyer M, Luders S, Kollmann K (1998) Hypertension and stroke-rationale behind the ACCESS trial. Acute Candesartan
Cilexetil Evaluation in Stroke Survivors. Basic Res Cardiol 93 Suppl 2:
69–78
Staessen JA, Gasowski J, Wang JG et al. (2000) Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355: 865–872
Staessen JA, Wang JG, Thijs L (2001) Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358: 1305–1315
Staessen JA, Wang JG, Thijs L (2002) Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials.
Am J Hypertens 15: 85S-93S

59.
60.
61.
58.
62.
Stamler J, Stamler R, Neaton JD (1993) Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med
153: 598–615
Strandgaard S (1996) Hypertension and stroke. J Hypertens Suppl 14:
S23–S27
Thrift AG, Donnan GA, McNeil JJ (1995) Epidemiology of intracerebral hemorrhage. Epidemiol Rev 17: 361–381
Thrift AG, McNeil JJ, Forbes A, Donnan GA (1998) Three important subgroups of hypertensive persons at greater risk of intracerebral hemorrhage. Melbourne Risk Factor Study Group. Hypertension 31:
1223–1229
Van Aken H, Puchstein C, Anger C, Lawin P (1983) The influence of urapidil, a new antihypertensive agent, on cerebral perfusion pressure in dogs with and without intracranial hypertension. Intensive Care Med 9:
123–126

63.
64.
65.
66.
Varon J, Marik PE (2000) The diagnosis and management of hypertensive crises. Chest 2000 118: 214–227
Vaughan CJ, Delanty N (2000) Hypertensive emergencies. Lancet 356:
411–417
Woo D, Sauerbeck LR, Kissela BM et al. (2002) Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke 33: 1190–1196
Wusten R, Hemelrijck J, Mattheussen M et al. (1990) Effect of nifedipine and urapidil on autoregulation of cerebral circulation in the presence of an intracranial space occupying lesion. Anasth Intensivther Notfallmed 25:
140–145

1.
Naumann GOH: Pathologie des Auges, Springer, Berlin Heidelberg New
York 1997
2.
3.
4.
5.
6.
Susic D: Hypertension, aging, and atherosclerosis: The endothelial interface. Med Clin North Am 81: 1238, 1997
Hayreh S: Hypertensive retinopathy. Ophthalmologica 198: 173, 1973
Tso M, Jampol L: Pathophysiology of hypertensive retinopathy.
Ophthalmology 89: 1132, 1982
Wagener HP, Clay GE, Gipner JF: Classification of retinal lesions in the presence of vascular hypertension: Report submitted by the commitee.
Trans Am Ophthalmol Soc 45: 57, 1947
Seitz R: Die Netzhautgefäße. Vergleichende ophthalmoskopische und histologische Studien an gesunden und kranken Augen. Stuttgart, Enke
1962: 1–176 Bücherei des Augenarztes

7.
8.
9.
10.
11.
12.
Becker RA: Hypertension and Arteriolosclerosis. In: Tasman W (ed)
Duane's clinical ophthalmology, vol 3. Lippincott Williams & Wilkins,
Kansas Boston
Stella K. Kim, A. Richard Christlieb: Hypertension and ist Ocular
Manifestations. In Principles and Practise of Ophthalmology, 2nd ed, W.B.
Saunders company
Bill A: Autonomic nervous control of uveal blood flow. Acta Physilo
Scand 56: 70, 1962
Bill, A: Ocular circulation. In Moses RA (ed): Adler's physiology of the eye: Clinical application, 7th edn. Mosby, St. Louis, 1981, p184
Ernest J: The effect of systolic hypertension on rhesus monkey eyes after ocular sympathectomy. Am J Ophtalmol 84: 341, 1977
Weiter J, Schachar R, Ernest J: Control of intraocular blood flow. Effects of sympathetic tone. Invest Opthalmol 12: 332, 1973

16.
17.
18.
19.
13.
14.
15.
Laties AM: Central retinal artery innervatin: Absence of adrenergic innervation to the intraocular branches. Arch Opthalmol 77: 405–409,
1967
Ehinger B: Adrenergic nerves to the eye and to related structures in man and Cynomolgus monkey. Invest Opthalmol Vis Sci 5: 42–52, 1966
Robinson F, Riva CE, Grunwald JE, et al: Retinal blood flow autoregulation in response to an acute increase of blood pressure. Invest
Opthalmol Vis Sci 27: 722–726, 1986
Hogan MJ, Zimmermann LE: Ophthalic pathology, 2nd edn. Saunders,
Philadelphia 1995
Scheie HG: Evaluation of ophthalmoscopic changes of hypertension and arteriolar sclerosis. Arch Ophthalmol 49: 117, 1953
Walsh J: Hypertensive retinopathy. Opthalmology 89: 1127, 1982
Keith NM, Wagener HP, Barker NW: Some different types of essential hypertension: Their course and prognosis. Am J Med Sci 197: 332, 1939

20.
21.
22.
Breslin DJ, Gifford RW, Fairbairn JF, Kearns TP: Prognostic importance of ophthalmoscopic findings in essential hypertension JAMA 195.91,
1966,
Leishman R: The eye in general vascular disease: Hypertension and arteriosclerosis. Br J Opthalmol 41: 641, 1957
Hubbard LD, Brothers RJ, King WN et al. Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the atherosclerosis risk in communities study. Ophthalmology 106:
2269–2280, 1999

1.
Folkow B. "Structural factor" in primary and secondary hypertension.
Hypertension 1990; 16: 89–101
2.
3.
4.
5.
Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension. Dual processes of remodeling and growth.
Hypertension. 1993; 21: 391–397
Mulvany MJ. Resistance vessel growth and remodelling. J Hum Hypertens
1995; 9: 479–485
Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG,
Korsgaard N, Mulvany MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension. 1991; 17:
626–635
Schiffrin EL, Ceng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years

7.
8.
9.
6.
10.
treatment with an angiotensin I converting enzyme inhibitor. Am J
Hypertens 1995; 8: 229–236
Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Muiesan P,
Giulini SM, Agabiti-Rosei E. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension. 1996; 28: 785–790
Lever AF. Slow pressor mechanisms in essential hypertension. J
Hypertens 1986; 4: 515–524
Lever AF, Harrap SB. Essential hypertension: a disorder of growth origins in childhood. J Hypertens 1992; 10: 101–120
Liao D, Arnett DK, Tyroler HA, Riley WA, Chambless LE, Szklo M,
Heiss G. Arterial stiffness and the development of hypertension. The
ARIC study. Hypertension. 1999; 34: 201–206
Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients.
Hypertension. 1999; 33: 1111–1117

13.
14.
15.
16.
11.
12.
O'Rourke M. Mechanical principles in arterial disease. Hypertension 1995;
26: 2–9
Bussy C, Boutouyrie P, Lacolley P, Challande P, Laurent S. Intrinsic stiffness of the carotid arterial wall material in essential hypertensives.
Hypertension. 2000; 35: 1049–1054
Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension. Hypertension 2000; 36: 312–318
Cosentino F, Lüscher TF. Effects of blood pressure and glucose on endothelial function. Curr Hypertens Rep 2001; 3: 79–88. 15
Vanhoutte PM. Endothelium-derived free radicals. J Clin Invest 2001;
107: 23–25
Hempel A, Maasch C, Heintze U, Lindschau C, Dietz R, Luft FC, Haller
H. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res. 1997; 81: 363–371

17.
18.
19.
20.
21.
Touyz RM. Molecular and cellular mechanisms regulating vascular function and structure. Can J Cardiol 2000; 16: 1137–1146
Hoyer J, Kohler R, Haase W, Distler A. Up-regulation of pressureactivated Ca(2+)-permeable cation channel in intact vascular endothelium of hypertensive rats. Proc Natl Acad Sci U S A. 1996; 93: 11253–11258
Rosenthal J, Thurnreiter M, Plaschke M, Geyer M, Reiter W, Dahlheim H.
Reninlike enzymes in human vasculature. Hypertension. 1990 Jun; 15(6 Pt
2): 848–853
Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M, Zimmermann
F, Ruf P, Hilgenfeldt U, Ganten U, et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci U S A. 1992; 89: 7806–7810
Mervaala E, Muller DN, Schmidt F, Park JK, Gross V, Bader M, Breu V,
Ganten D, Haller H, Luft FC. Blood pressure-independent effects in rats

22.
23.
24.
25.
with human renin and angiotensinogen genes. Hypertension. 2000; 35:
587–594
Byrom FB, Dodson LF. The causation of acute arterial necrosis in hypertensive disease. J Pathol Bact 1948; 60: 37–51
Luft FC, Mervaala E, Muller DN, Gross V, Schmidt F, Park JK, Schmitz
C, Lippoldt A, Breu V, Dechend R, Dragun D, Schneider W, Ganten D,
Haller H. Hypertension-induced end-organ damage: A new transgenic approach to an old problem. Hypertension. 1999; 33(1 Pt 2): 212–218
Mervaala EM, Muller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun
D, Ganten D, Haller H, Luft FC. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension.
1999; 33(1 Pt 2): 389–395
Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A,
Theuer J, Breu V, Ganten D, Haller H, Luft FC. NF-kappaB inhibition

26.
27.
28.
ameliorates angiotensin II-induced inflammatory damage in rats.
Hypertension. 2000; 35(1 Pt 2): 193–201
Muller DN, Heissmeyer V, Dechend R, Hampich F, Park JK, Fiebeler A,
Shagdarsuren E, Theuer J, Elger M, Pilz B, Breu V, Schroer K, Ganten D,
Dietz R, Haller H, Scheidereit C, Luft FC. Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage. FASEB J. 2001; 15:
1822–1824
Muller DN, Mervaala EM, Dechend R, Fiebeler A, Park JK, Schmidt F,
Theuer J, Breu V, Mackman N, Luther T, Schneider W, Gulba D, Ganten
D, Haller H, Luft FC. Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J
Pathol. 2000; 157: 111–122
Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F,
Bieringer M, Schafer O, Lindschau C, Schneider W, Ganten D, Luft FC,
Haller H. Cerivastatin prevents angiotensin II-induced renal injury

29.
30.
31.
independent of blood pressure- and cholesterol-lowering effects. Kidney
Int. 2000; 58: 1420–1430
Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E,
Bieringer M, Gulba D, Dietz R, Luft FC, Haller H. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation. 2001; 104: 576–581
Muller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E,
Breu V, Loffler BM, Ganten D, Schneider W, Haller H, Luft FC. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin IIinduced end-organ damage. Hypertension. 2000; 36: 282–290
Muller DN, Mullally A, Dechend R, Park JK, Fiebeler A, Pilz B, Loffler
BM, Blum-Kaelin D, Masur S, Dehmlow H, Aebi JD, Haller H, Luft FC.
Endothelin-Converting Enzyme Inhibition Ameliorates Angiotensin II-
Induced Cardiac Damage. Hypertension. 2002; 40: 840–846

32.
33.
34.
35.
Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M,
Shagdarsuren E, Breu V, Haller H, Luft FC. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin IIinduced cardiac injury. Hypertension. 2001; 37(2 Part 2): 787–793
Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich
F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J,
Heidecke H, Haller H, Zenke M, Luft FC. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol. 2002;
161: 1679–1693
Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A,
Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft
FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999; 103: 945–952
Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner
A, Gulba DC, Mackman N, Haller H, Luft FC. AT(1) receptor agonistic

36.
37.
38.
39.
antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation. 2000; 101: 2382–2387
Dechend R, Müller DN, Viedt C, Wallukat G, Park J-K, Theuer J, Barta P,
Homuth V, Fiebeler A, Kreuzer J, Dietz R, Haller H, Luft FC. AT1 receptor antibodies from preeclamptic patients stimulate NADPH oxidase.
Circulation 2003 (in press)
Luther HP, Homuth V, Wallukat G. Alpha 1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension. 1997 Feb;
29(2): 678–682
Olsen F. Type and course of the inflammatory cellular reaction in acute angiotensin-hypertensive vascular disease in rats. Acta Pathol Microbiol
Scand [A]. 1970; 78(2): 143–150
Olsen F. The secondary and tertiary inflammatory cellular reaction in arterioles damaged by acute angiotensin-hypertension in rats. Acta Pathol
Microbiol Scand [A]. 1970; 78(4): 451–457

40.
41.
42.
43.
Olsen F. Evidence for an immunological factor in the hypertensive vascular disease. Acta Pathol Microbiol Scand [A]. 1971; 79(1): 22–26
Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF,
Schiffrin EL. PPARalpha Activator Effects on Ang II-Induced Vascular
Oxidative Stress and Inflammation. Hypertension. 2002 Dec; 40(6): 866–
871
Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S,
Egido J. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl. 2002 Dec;
(82): 12–22
Chen K, Wei Y, Sharp GC, Braley-Mullen H. Inhibition of TGFbeta1 by anti-TGFbeta1 antibody or lisinopril reduces thyroid fibrosis in granulomatous experimental autoimmune thyroiditis. J Immunol. 2002
Dec 1; 169(11): 6530–6538

44.
45.
Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, Zanchi C,
Abbate M, Remuzzi G. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol.
2002 Dec; 13(12): 2898–2908
Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC.
Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension. 2001; 37(2
Part 2): 781–786

1.
Deutsche Liga zur Bekämpfung des hohen Blutdruckes (2001) Leitlinien für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen
2.
3.
4.
Hypertonie. Dtsch Med Wochenschr 126: S201–S238
Joint-National-Committee (1997) The sixth report of the Joint National
Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157: 2413–2446.
Kaplan NM (1997) Hypertensive crises. In: Braunawald E (ed) Heart disease. Saunders, Philadelphia, pp 832–839
Kaplan NM (1994) Management of hypertensive emergencies. Lancet
344: 1335–1338